The Beauty Health Company demonstrates a strong recurring revenue model with defensible consumables sales that underpin margin expansion and operational resilience. Growth sustainability is supported by expanding installed base and innovation pipeline, while margin durability benefits from a favora…
The Beauty Health Company (SKIN) Q1 2025: Consumables Drive 8% Growth Amid Equipment Sales Decline
Beauty Health's first quarter highlights the resilience of its recurring consumables revenue, offsetting a steep decline in equipment sales amid macroeconomic pressures. Strategic moves including U.S. production consolidation and China distributor transition underpin margin expansion and operational agility. Forward momentum hinges on innovation launches and provider engagement amid tariff-related cost headwinds.
Summary
- Recurring Revenue Strength: Consumables growth offsets equipment sales softness, underscoring business resilience.
- Operational Realignment: U.S. production consolidation and China distributor shift reduce tariff exposure and complexity.
- Innovation Pipeline Activation: Upcoming product launches and provider loyalty programs aim to fuel sustainable growth.
Business Overview
The Beauty Health Company operates at the intersection of medical technology and beauty, generating revenue primarily through the sale of hydradermabrasion delivery systems and consumable products. Its business is segmented into delivery systems, which include capital equipment used by providers, and consumables, comprising recurring products used with these devices. The company’s flagship brand, Hydrafacial, along with SkinStylus and Keravive, anchor its portfolio, with consumables representing over 70% of total revenue, reflecting the recurring revenue model that underpins the business.
Performance Analysis
In Q1 2025, Beauty Health reported net sales of $69.6 million, down 14.5% year-over-year, driven by a 43.5% decline in delivery system sales to $20.2 million. This decline was most pronounced in the Asia-Pacific (APAC) and Europe, Middle East, and Africa (EMEA) regions, reflecting macroeconomic headwinds and strategic shifts such as the transition to a distributor model in China. However, consumables sales grew 8.2% to $49.4 million, with strong regional performances including a 42.6% increase in APAC consumables, driven by disciplined pricing and reduced discounting.
Gross margin expanded significantly to 69.8%, up nearly 10 percentage points year-over-year, and adjusted gross margin reached 71.9%, reflecting favorable product mix shifts towards higher-margin consumables, improved inventory management, and lower excess and obsolete inventory charges. Adjusted EBITDA improved markedly to $7.3 million, from $0.4 million in the prior year, supported by operational cost discipline and gross margin expansion despite lower top-line sales.
- Margin Expansion Levers: Mix shift to consumables and enhanced supply chain efficiency drove gross margin improvement.
- Regional Variability: APAC and EMEA delivery system sales declined sharply, while Americas showed more resilience.
- Install Base Growth: Active installed delivery systems increased to 35,014 units, supporting consumables revenue growth.
Overall, the quarter reflects a business navigating macro challenges by leveraging its recurring revenue model and operational restructuring to protect profitability and lay groundwork for future growth.
Executive Commentary
"We exceeded both revenue and adjusted EBITDA guidance, driven by gross profit growth and meaningful cost efficiencies. Despite macroeconomic pressures that impacted device sales, consumables revenue remained resilient, reinforcing the strength of our recurring revenue model and sustained consumer demand."
Marla Beck, Chief Executive Officer
"Gross margins came in strong, driven primarily by disciplined demand planning, overall management of inventory, a favorable mix towards consumable net sales, and improved operational processes. This led to reduced excess and obsolete inventory charges and reduced overhead spend."
Mike Monahan, Chief Financial Officer
Strategic Positioning
1. Commercial Execution Enhancement
Beauty Health is refining its go-to-market approach with a restructured sales organization, pricing flexibility, and analytical rigor to drive smarter execution. The introduction of a good, better, best device portfolio expands provider access with lower-priced options, which represented 36% of system sales in Q1. These efforts aim to capture market share and improve sales efficiency amid a challenging capital equipment environment.
2. Innovation Acceleration
The company is reigniting its product pipeline with clinically validated launches, including a hydrophilic booster with proprietary PEP9 complex scheduled for June and multiple new treatment tips to extend its scalp care solution. The back bar initiative, launching in H2 2025, introduces skincare products for in-room use, complementing treatments and enhancing provider revenue. A consumer-facing skincare line is planned for early 2026, broadening the brand's reach beyond professional settings.
3. Provider Partnership Deepening
Strong relationships with providers form the foundation of growth. The relaunch of the U.S. loyalty program in Q3 2025 aims to increase provider engagement and incentivize commitment. Investments in brand campaigns and consumer engagement are designed to drive traffic to providers and support incremental sales, particularly in the medical and wellness sectors, which are exhibiting robust growth.
4. Operational Realignment and Tariff Mitigation
Shifting production to Long Beach, California, consolidates manufacturing, enhances quality, and significantly reduces tariff exposure. The transition of China operations to a distributor model simplifies the operational footprint and lowers capital intensity, although some tariff exposure on consumables remains. The company estimates a $5 million tariff cost impact in 2025, factored into guidance, with ongoing efforts to further onshore supply chains.
5. Financial Discipline and Cost Management
Operating expenses declined 7.3% year-over-year, driven by lower selling and marketing spend and reduced research and development costs, partially offset by increased legal fees and restructuring expenses. The company’s focus on cost discipline supports adjusted EBITDA expansion despite sales headwinds, positioning it for improved profitability as market conditions evolve.
Key Considerations
Beauty Health’s Q1 results underscore the critical role of its recurring consumables revenue in offsetting capital equipment softness amid macroeconomic uncertainty and tariff challenges. The company’s strategic initiatives are focused on enhancing commercial execution, accelerating innovation, and deepening provider relationships to drive sustainable growth.
Key Considerations:
- Recurring Revenue Resilience: Consumables now represent over 70% of revenue, providing stability amid equipment sales volatility.
- Geographic Exposure: APAC and EMEA delivery system sales face pressure, with China transitioning to a distributor model impacting near-term revenue.
- Tariff Impact Management: Production consolidation and inventory positioning mitigate tariff risks, though $5 million cost headwind remains in 2025.
- Innovation as Growth Catalyst: Upcoming product launches and back bar skincare line aim to deepen consumer engagement and provider revenue.
- Provider Focus: Loyalty program relaunch and targeted marketing investments seek to strengthen provider ecosystem and sales pull-through.
Risks
Risks include continued macroeconomic uncertainty limiting capital equipment purchases, tariff volatility affecting cost structure, and the execution risks associated with the China distributor transition. Competitive pressures in the medtech beauty space and potential consumer pullback in luxury segments also pose challenges to revenue growth and margin expansion.
Forward Outlook
For Q2 2025, Beauty Health guided net sales between $71 million and $76 million and adjusted EBITDA of $2 million to $4 million. Full-year 2025 guidance anticipates net sales of $270 million to $300 million and adjusted EBITDA of $15 million to $25 million, reflecting ongoing delivery system sales pressure and tariff-related cost impacts. Management assumes no material deterioration in market conditions beyond current expectations and excludes unannounced acquisitions or financings. Key factors influencing guidance include tariff cost absorption, consumables growth trajectory, and execution of innovation and commercial initiatives.
Takeaways
Beauty Health’s Q1 performance highlights the strength of its recurring revenue model and operational agility in a challenging environment. The company’s strategic focus on commercial execution, innovation, and provider engagement is well-aligned with market dynamics, though near-term growth is tempered by equipment sales declines and tariff cost pressures.
- Margin Leverage Amid Sales Pressure: Operational improvements and favorable product mix underpin margin expansion despite lower equipment sales.
- Strategic Realignment in China: Distributor model transition reduces complexity but presents short-term revenue headwinds and tariff exposure.
- Innovation Pipeline as Growth Driver: New product launches and back bar skincare initiatives are poised to enhance consumer engagement and provider revenue streams.
Conclusion
The Beauty Health Company’s Q1 results reflect disciplined execution of its transformation strategy, with consumables growth and margin expansion offsetting capital equipment softness. Strategic initiatives around innovation, commercial execution, and operational realignment position the company to navigate near-term headwinds and build a foundation for sustainable long-term growth.
Industry Read-Through
Beauty Health’s experience underscores the increasing importance of recurring consumables revenue in medtech beauty companies to buffer against capital equipment cyclicality. The strategic shift toward flexible pricing and diversified device portfolios reflects broader industry trends to expand market access amid macroeconomic uncertainty. Additionally, tariff mitigation through production onshoring and distribution model adjustments signals a growing operational focus across the sector to manage geopolitical cost risks. Innovation pipelines grounded in clinical validation remain critical to maintaining competitive differentiation in a crowded aesthetic treatment landscape.